½ÃÀ庸°í¼­
»óǰÄÚµå
1386384

DNA ¹é½Å ½ÃÀå º¸°í¼­ : µ¿Çâ, ¿¹Ãø ¹× °æÀï ºÐ¼®(-2030³â)

DNA Vaccine Market Report: Trends, Forecast and Competitive Analysis to 2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Lucintel | ÆäÀÌÁö Á¤º¸: ¿µ¹® 150 Pages | ¹è¼Û¾È³» : 3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

DNA ¹é½ÅÀÇ µ¿Çâ°ú Àü¸Á

¼¼°è DNA ¹é½Å ½ÃÀåÀº 2024³âºÎÅÍ 2030³â±îÁö 6.5%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î ¼ºÀåÀ» Áö¼ÓÇÏ¿© 2030³â±îÁö ¾à 8¾ï ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ ½ÃÀåÀÇ ÁÖ¿ä ÃËÁø¿äÀÎÀº Àΰ£°ú µ¿¹°ÀÇ ¾Ï ¹× °¨¿°¼º Áúȯ Áõ°¡¿Í Ç׿øÀ» Á÷Á¢ »ý»êÇϱâ À§ÇØ À¯ÀüÀÚ Á¶ÀÛµÈ DNA ¼¼Æ÷¿¡¼­ ÀÌ·¯ÇÑ ¹é½Å¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí Àֱ⠶§¹®ÀÔ´Ï´Ù. ¼¼°è DNA ¹é½Å ½ÃÀåÀÇ ¹Ì·¡´Â µ¿¹°º´¿ø°ú µ¿¹° Ŭ¸®´Ð ½ÃÀå ±âȸ°¡ À¯¸ÁÇÑ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

DNA ¹é½Å ½ÃÀå ÀλçÀÌÆ®

LucintelÀº µ¿¹°ÀÇ °³ Èæ»öÁ¾ ¾ÏÀÇ È®»êÀ» ¹æÁöÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» ÇÏ´Â ¿Â¼ÁÆ®°¡ °¡Àå Å« ºÎ¹®À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óÇϰí ÀÖ½À´Ï´Ù.

ºÏ¹Ì¿¡´Â ÁÖ¿ä ±â¾÷ÀÌ Á¸ÀçÇÏ°í ¼öÀÇÇÐ Á¶Á÷ ü°è°¡ È®¸³µÇ¾î Àֱ⠶§¹®¿¡ ¿¹Ãø ±â°£ µ¿¾È °¡Àå ³ôÀº ¼ºÀåÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÀÌ º¸°í¼­´Â ´ÙÀ½°ú °°Àº 11°¡Áö ÁÖ¿ä Áú¹®¿¡ ´ëÇÑ ´äº¯À» ´ã°í ÀÖ½À´Ï´Ù.

  • Q.1. ½ÃÀå ºÎ¹® Áß °¡Àå À¯¸ÁÇÏ°í ¼ºÀ强ÀÌ ³ôÀº ±âȸ´Â ¹«¾ùÀΰ¡?
  • Q.2. ¾î¶² ºÎ¹®ÀÌ ´õ ºü¸¥ ¼Óµµ·Î ¼ºÀåÇÒ °ÍÀ̸ç, ±× ÀÌÀ¯´Â ¹«¾ùÀΰ¡?
  • Q.3. ÇâÈÄ ¼ºÀåÀÌ °¡¼ÓÈ­µÉ °ÍÀ¸·Î ¿¹»óµÇ´Â Áö¿ª°ú ±× ÀÌÀ¯´Â?
  • Q.4. ½ÃÀå ¿ªÇп¡ ¿µÇâÀ» ¹ÌÄ¡´Â ÁÖ¿ä ¿äÀÎÀº? ½ÃÀåÀÇ ÁÖ¿ä °úÁ¦¿Í ºñÁî´Ï½º ¸®½ºÅ©´Â ¹«¾ùÀΰ¡?
  • Q.5. ÀÌ ½ÃÀå¿¡¼­ÀÇ ºñÁî´Ï½º ¸®½ºÅ©¿Í °æÀï À§ÇùÀº ¹«¾ùÀΰ¡?
  • Q.6. ÀÌ ½ÃÀåÀÇ »õ·Î¿î Æ®·»µå¿Í ±× ÀÌÀ¯´Â?
  • Q.7. ½ÃÀå¿¡¼­ÀÇ °í°´ ¼ö¿ä º¯È­¿¡´Â ¾î¶² °ÍµéÀÌ Àִ°¡?
  • Q.8. ÀÌ ½ÃÀåÀÇ »õ·Î¿î ¹ßÀü°ú ±× ¹ßÀüÀ» ÁÖµµÇϰí ÀÖ´Â ±â¾÷Àº?
  • Q.9. ÀÌ ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷Àº? ÁÖ¿ä ±â¾÷µéÀº »ç¾÷ ¼ºÀåÀ» À§ÇØ ¾î¶² Àü·«Àû ³ë·ÂÀ» ±â¿ïÀ̰í Àִ°¡?
  • Q.10. ÀÌ ½ÃÀåÀÇ °æÀï Á¦Ç°¿¡´Â ¾î¶² °ÍµéÀÌ ÀÖÀ¸¸ç, ¼ÒÀç ¹× Á¦Ç° ´ëü¿¡ µû¸¥ ½ÃÀå Á¡À¯À² Ç϶ôÀÇ À§ÇùÀº ¾î´À Á¤µµÀΰ¡?
  • Q.11. Áö³­ 5³â°£ ¾î¶² M&A°¡ ÀÌ·ç¾îÁ³°í, ¾÷°è¿¡ ¾î¶² ¿µÇâÀ» ¹ÌÃÆ´Â°¡?

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ¼¼°èÀÇ DNA ¹é½Å ½ÃÀå : ½ÃÀå ¿ªÇÐ

  • ¼­·Ð, ¹è°æ, ºÐ·ù
  • °ø±Þ¸Á
  • ¾÷°è ÃËÁø¿äÀΰú °úÁ¦

Á¦3Àå ½ÃÀå µ¿Çâ ¹× ¿¹Ãø ºÐ¼®(2018-2030³â)

  • °Å½Ã°æÁ¦ µ¿Çâ(2018-2023³â)°ú ¿¹Ãø(2024-2030³â)
  • ¼¼°èÀÇ DNA ¹é½Å ½ÃÀå µ¿Çâ(2018-2023³â)°ú ¿¹Ãø(2024-2030³â)
  • Á¦Ç° À¯Çüº° ¼¼°èÀÇ DNA ¹é½Å ½ÃÀå
    • Oncept
    • West Nile-Innovator
    • Apex-IHN
  • À¯Çüº° ¼¼°èÀÇ DNA ¹é½Å ½ÃÀå
    • Ä¡·á ¹é½Å
    • ¿¹¹æ ¹é½Å
  • ÃÖÁ¾ ¿ëµµº° ¼¼°èÀÇ DNA ¹é½Å ½ÃÀå
    • µ¿¹° Ŭ¸®´Ð
    • µ¿¹° º´¿ø

Á¦4Àå Áö¿ªº° ½ÃÀå µ¿Çâ ¹× ¿¹Ãø ºÐ¼®(2018-2030³â)

  • Áö¿ªº° ¼¼°èÀÇ DNA ¹é½Å ½ÃÀå
  • ºÏ¹ÌÀÇ DNA ¹é½Å ½ÃÀå
  • À¯·´ÀÇ DNA ¹é½Å ½ÃÀå
  • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ DNA ¹é½Å ½ÃÀå
  • ±âŸ Áö¿ªÀÇ DNA ¹é½Å ½ÃÀå

Á¦5Àå °æÀï ºÐ¼®

  • Á¦Ç° Æ÷Æ®Æú¸®¿À ºÐ¼®
  • ¿î¿µ»ó ÅëÇÕ
  • PorterÀÇ Five Forces ºÐ¼®

Á¦6Àå ¼ºÀå ±âȸ¿Í Àü·«Àû ºÐ¼®

  • ¼ºÀå ±âȸ ºÐ¼®
    • Á¦Ç° À¯Çüº° ¼¼°èÀÇ DNA ¹é½Å ½ÃÀå ¼ºÀå ±âȸ
    • À¯Çüº° ¼¼°èÀÇ DNA ¹é½Å ½ÃÀå ¼ºÀå ±âȸ
    • ÃÖÁ¾ ¿ëµµº° ¼¼°èÀÇ DNA ¹é½Å ½ÃÀå ¼ºÀå ±âȸ
    • Áö¿ªº° ¼¼°èÀÇ DNA ¹é½Å ½ÃÀå ¼ºÀå ±âȸ
  • ¼¼°è DNA ¹é½Å ½ÃÀåÀÇ »õ·Î¿î µ¿Çâ
  • Àü·«Àû ºÐ¼®
    • ½ÅÁ¦Ç° °³¹ß
    • ¼¼°èÀÇ DNA ¹é½Å ½ÃÀå ´É·Â È®´ë
    • ¼¼°è DNA ¹é½Å ½ÃÀåÀÇ ÀμöÇÕº´(M&A) ¹× ÇÕÀÛÅõÀÚ(JV)
    • ÀÎÁõ ¹× ¶óÀ̼±½Ì

Á¦7Àå À¯·Â ±â¾÷ÀÇ ±â¾÷ °³¿ä

  • Geovax Labs
  • Viatris
  • Inovio Pharmaceuticals
  • Zydus Cadila
  • Geneone Life Science
  • Eli-Lilly
  • Zoetis
  • Takara Holdings
  • Boehringer Ingelheim
  • Genexine
LSH 23.12.06

DNA Vaccine Trends and Forecast

The future of the global DNA vaccine market looks promising with opportunities in the veterinary clinic and veterinary hospital markets. The global DNA vaccine market is expected to reach an estimated $0.8 billion by 2030 with a CAGR of 6.5% from 2024 to 2030. The major drivers for this market are rising occurrence of cases of cancer and infectious diseases in human and animals and growing demand for these vaccines among genetically engineered DNA cells to directly produce an antigen.

A more than 150-page report is developed to help in your business decisions.

DNA Vaccine by Segment

The study includes a forecast for the global DNA vaccine by product type, type, end use, and region.

DNA Vaccine Market by Product Type [Shipment Analysis by Value from 2018 to 2030]:

  • Oncept
  • West Nile-Innovator
  • Apex-IHN

DNA Vaccine Market by Type [Shipment Analysis by Value from 2018 to 2030]:

  • Therapeutic Vaccines
  • Prophylactic Vaccines

DNA Vaccine Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

  • Veterinary Clinics
  • Veterinary Hospitals

DNA Vaccine Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of DNA Vaccine Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies DNA vaccine companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the DNA vaccine companies profiled in this report include-

  • Geovax Labs
  • Viatris
  • Inovio Pharmaceuticals
  • Zydus Cadila
  • Geneone Life Science
  • Eli-Lilly
  • Zoetis
  • Takara Holdings
  • Boehringer Ingelheim
  • Genexine

DNA Vaccine Market Insights

Lucintel forecasts that oncept will remain the largest segment due to its significant usage to avoid prevalence of canine melanoma cancer in animals.

North America is expected to witness highest growth over the forecast period due to the presence of major key players and existence of well-established veterinary organizational structures in the region.

Features of the Global DNA Vaccine Market

Market Size Estimates: DNA vaccine market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: DNA vaccine market size by product type, type, end use, and region in terms of value ($B).

Regional Analysis: DNA vaccine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different product types, types, end uses, and regions for the DNA vaccine market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the DNA vaccine market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q.1 What is the DNA vaccine market size?

Answer: The global DNA vaccine market is expected to reach an estimated $0.8 billion by 2030.

Q.2 What is the growth forecast for DNA vaccine market?

Answer: The global DNA vaccine market is expected to grow with a CAGR of 6.5% from 2024 to 2030.

Q.3 What are the major drivers influencing the growth of the DNA vaccine market?

Answer: The major drivers for this market are rising occurrence of cases of cancer and infectious diseases in human and animals and growing demand for these vaccines among genetically engineered DNA cells to directly produce an antigen.

Q4. What are the major segments for DNA vaccine market?

Answer: The future of the DNA vaccine market looks promising with opportunities in the therapeutic and prophylactic markets.

Q5. Who are the key DNA vaccine market companies?

Answer: Some of the key DNA vaccine companies are as follows:

  • Geovax Labs
  • Viatris
  • Inovio Pharmaceuticals
  • Zydus Cadila
  • Geneone Life Science
  • Eli-Lilly
  • Zoetis
  • Takara Holdings
  • Boehringer Ingelheim
  • Genexine

Q6. Which DNA vaccine market segment will be the largest in future?

Answer: Lucintel forecasts that oncept will remain the largest segment due to its significant usage to avoid prevalence of canine melanoma cancer in animals.

Q7. In DNA vaccine market, which region is expected to be the largest in next 5 years?

Answer: North America is expected to witness highest growth over the forecast period due to the presence of major key players and existence of well-established veterinary organizational structures in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the DNA vaccine market by product type (oncept, west nile-innovator, and apex-IHN), type (therapeutic vaccines and prophylactic vaccines), end use (veterinary clinics and veterinary hospitals), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global DNA Vaccine Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global DNA Vaccine Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global DNA Vaccine Market by Product Type
    • 3.3.1: Oncept
    • 3.3.2: West Nile-Innovator
    • 3.3.3: Apex-IHN
  • 3.4: Global DNA Vaccine Market by Type
    • 3.4.1: Therapeutic Vaccines
    • 3.4.2: Prophylactic Vaccines
  • 3.5: Global DNA Vaccine Market by End Use
    • 3.5.1: Veterinary Clinics
    • 3.5.2: Veterinary Hospitals

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global DNA Vaccine Market by Region
  • 4.2: North American DNA Vaccine Market
    • 4.2.2: North American DNA Vaccine Market by Type: Therapeutic Vaccines and Prophylactic Vaccines
  • 4.3: European DNA Vaccine Market
    • 4.3.1: European DNA Vaccine Market by Product Type: Oncept, West Nile-Innovator, and Apex-IHN
    • 4.3.2: European DNA Vaccine Market by Type: Therapeutic Vaccines and Prophylactic Vaccines
  • 4.4: APAC DNA Vaccine Market
    • 4.4.1: APAC DNA Vaccine Market by Product Type: Oncept, West Nile-Innovator, and Apex-IHN
    • 4.4.2: APAC DNA Vaccine Market by Type: Therapeutic Vaccines and Prophylactic Vaccines
  • 4.5: ROW DNA Vaccine Market
    • 4.5.1: ROW DNA Vaccine Market by Product Type: Oncept, West Nile-Innovator, and Apex-IHN
    • 4.5.2: ROW DNA Vaccine Market by Type: Therapeutic Vaccines and Prophylactic Vaccines

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global DNA Vaccine Market by Product Type
    • 6.1.2: Growth Opportunities for the Global DNA Vaccine Market by Type
    • 6.1.3: Growth Opportunities for the Global DNA Vaccine Market by End Use
    • 6.1.4: Growth Opportunities for the Global DNA Vaccine Market by Region
  • 6.2: Emerging Trends in the Global DNA Vaccine Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global DNA Vaccine Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global DNA Vaccine Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Geovax Labs
  • 7.2: Viatris
  • 7.3: Inovio Pharmaceuticals
  • 7.4: Zydus Cadila
  • 7.5: Geneone Life Science
  • 7.6: Eli-Lilly
  • 7.7: Zoetis
  • 7.8: Takara Holdings
  • 7.9: Boehringer Ingelheim
  • 7.10: Genexine
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦